Transplant and Cellular Therapy Physician

Company/Institution: University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
Department: Department of Medicine
Location: Baltimore, MD, USA
Degree Requirements: MD, PhD and/or MD, DO, Board Eligible, Board Certified Salary: Not available
Job Type: Faculty, Patient Care, Research Posted: March 30, 2022
Job Setting: Medical School, Hospital/Clinical Facility, Non-Profit Research Institute Application Period: January 26-April 29, 2023

University of Maryland Hematology/Oncology (Position 3-309-1118): The Department of Medicine of the University of Maryland Medical School of Medicine and the NCI-designated Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) located in Baltimore, MD are recruiting for a full-time faculty member with a focus on Transplant and Cellular Therapy to join our distinguished group of medical professionals. Our transplant and cellular therapy (TCT) program consisting of an interdisciplinary team inclusive of medical oncologists/hematologists, radiation oncologists, pathologists, nurses, apheresis and cell processing specialists, nutritionists, social workers, and genetic counselors is recognized as a Center of Excellence and is accredited by FACT based on rigorous national standards in the fields of both stem cell transplantation and immune cell therapy product transplantation. Our team is actively engaged in discovering new ways to treat patients with cancer, including development of next generation cellular therapeutics. The essential functions of the position include outpatient consultations and longitudinal patient care, teaching and mentoring of Hematology/Oncology fellows, residents and medical students. Active participation in clinical research is expected. Furthermore, candidates with a strong interest and or published literature relating to conducting clinical/translational research centered on cellular immunotherapy are preferred. Expected faculty rank is Assistant Professor or higher, however, final rank, tenure status and salary will be commensurate with the selected candidate’s qualifications and experience. We are seeking a candidate with excellent training and expertise in allogeneic and autologous stem cell transplantation and especially engineered immune cell (CART) therapies. The ideal candidate will have strong interest and experience in the conduct, design and development of clinical trials of novel immune cell therapies for hematologic malignancies and solid tumors. In addition, the candidate will have the opportunity the lead translational research in the area of engineered immune cell therapy in close collaboration with our translational immunology and immunomonitoring core laboratories as well as our newly operationalized GMP laboratory. Candidates must possess an M.D. or D.O. degree and must be board certified or board-eligible by the ABIM in internal medicine and hematology and/or medical oncology and be eligible for a medical license in Maryland. In addition, the candidate must have completed at least one year of clinical experience managing both allogeneic and autologous transplant patients either beyond Hem/Onc fellowship training, or in some cases within the context of fellowship, if the program or the candidate had a particularly strong focus on transplantation. The ability and experience to conduct scholarly/clinical/translational research is required. UMB is an equal opportunity/affirmative action employer. All qualified applicants will receive consideration for employment without regard to sex, gender identity, sexual orientation, race, color, religion, national origin, disability, protected Veteran status, age, or any other characteristic protected by law or policy. We value diversity and how it enriches our academic and scientific community and strive toward cultivating an inclusive environment that supports all employees. UMB was ranked 13th in ‘Forbes’ 2021 America’s Best Large Employers Survey. If you need a reasonable accommodation for a disability, for any part of the recruitment process, please contact us at and let us know the nature of your request and your contact information. Please note that only inquiries concerning a request for reasonable accommodation will be responded to from this email address. For additional questions after application, please email

About the Employer

The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) is a joint program of the University of Maryland School of Medicine and the University of Maryland Medical System. In 2008, UMGCC was named a National Cancer Institute (NCI)-designated cancer center, one of only 64 such centers in the country. UMGCCC is also ranked among the nation's 50 top cancer centers by U.S. News and World Report. Within the School of Medicine and the other UMB schools, UMGCCC serves as the umbrella for all cancer-related activities on campus. Cancer Center members have academic appointments in various clinical and basic science departments of the School of Medicine and the schools of pharmacy, dentistry, social work, and nursing. Activities of the Cancer Center include basic and translational cancer research, student and house officer teaching, and a strong focus on new therapies in both an inpatient 46-bed unit and outpatient setting. The bone marrow transplant unit, on the 9th floor of the Gudelsky Tower, comprises 16 private rooms along with nursing and staff support space. In addition to full-time attending services on medical oncology and hematology, Cancer Center members participate in multidisciplinary clinical programs centered around specific cancers (e.g., breast, thoracic, genitourinary, gynecologic, head and neck, gastroenterologic and hematologic malignancies) with specialists from surgical and radiation oncology to provide integrated care for the cancer patient. The UMGCCC has substantial NIH funding. The center is a strong participant in new drug development and trials, and is a member of several national cooperative groups. UMGCCC has a historic and sustained track record of clinical trials in human cancer. In FY 2008, 1,030 patients were accrued to clinical trials across UMGCCC and its affiliates. African Americans represent more than 40 percent of our patients, and nearly half of them take part in clinical trials at our Cancer Center. The Cancer Center has also established strong translational research programs in experimental therapeutics, hormone responsive cancers, molecular biology and genetics, viral oncology, tumor immunology, and cancer prevention and control. Cancer Center members have a strong commitment to intra- and inter-institutional cooperative cancer research.

How to Apply

When applying, please submit a current CV, a brief statement summarizing clinical and research interests, and names of four references. Though not required, you are also invited to include a perspective statement on equity, diversity, inclusion and civility. Qualified candidates should apply online at the following link:

Contact Information
Dept of Medicine
22 S. Greene St., Room N3E10
Baltimore, MD 21201 USA

back to top